Shares of RAPT Therapeutics (NASDAQ:RAPT) plunged 46% in early trading Monday after the company said it was scrapping development of its drug candidate zelnecirnon due to negative FDA feedback.
RAPT (RAPT) had been evaluating zelnecirnon for the treatment of
